---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-001570"
form_type: "8-K"
ticker: "ABPO"
cik: "0001893219"
company_name: "Abpro Holdings, Inc."
filed_at: "2026-01-06T23:59:59+00:00"
generated_at: "2026-05-16T11:33:57.678805+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Abpro and Celltrion announce FDA IND clearance for lead multispecific antibody ABP-102 / CT-P72

## Summary
- FDA cleared IND for ABP-102 / CT-P72, a multispecific HER2 × CD3 T-cell engager targeting HER2-positive solid tumors.
- Phase 1 clinical trial anticipated to commence in H1 2026, led by Celltrion under co-development collaboration.
- Preclinical data showed selective antitumor activity in HER2-high models and was well tolerated in NHP studies up to 80 mg/kg.
- Candidate designed to enhance tumor selectivity and limit activity in HER2-low tissues, aiming to reduce cytokine release syndrome risk.

## SEC filing metadata
- accession: 0001213900-26-001570
- form_type: 8-K
- ticker: ABPO
- cik: 0001893219
- company_name: Abpro Holdings, Inc.
- filed_at: 2026-01-06T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1893219/000121390026001570/0001213900-26-001570-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1893219/000121390026001570/ea0271844-8k_abpro.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-001570
- JSON: https://secwatch.observer/filing/0001213900-26-001570.json
- Plain text: https://secwatch.observer/filing/0001213900-26-001570.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.